Your browser is no longer supported. Please, upgrade your browser.
CLVS Clovis Oncology, Inc. daily Stock Chart
Clovis Oncology, Inc.
Index- P/E- EPS (ttm)-6.07 Insider Own0.40% Shs Outstand88.20M Perf Week-10.69%
Market Cap508.72M Forward P/E- EPS next Y-2.59 Insider Trans-6.83% Shs Float85.08M Perf Month-19.02%
Income-385.20M PEG- EPS next Q-0.99 Inst Own55.20% Short Float46.04% Perf Quarter-7.81%
Sales159.40M P/S3.19 EPS this Y-5.20% Inst Trans0.27% Short Ratio8.07 Perf Half Y-37.57%
Book/sh-1.21 P/B- EPS next Y40.20% ROA-58.90% Target Price9.00 Perf Year66.42%
Cash/sh- P/C- EPS next 5Y66.10% ROE316.90% 52W Range2.93 - 17.37 Perf YTD-45.08%
Dividend- P/FCF- EPS past 5Y-9.50% ROI-76.50% 52W High-67.04% Beta2.30
Dividend %- Quick Ratio2.60 Sales past 5Y60.00% Gross Margin75.40% 52W Low95.39% ATR0.47
Employees484 Current Ratio2.90 Sales Q/Q20.90% Oper. Margin- RSI (14)46.56 Volatility7.07% 7.02%
OptionableYes Debt/Eq- EPS Q/Q49.50% Profit Margin- Rel Volume0.71 Prev Close5.72
ShortableYes LT Debt/Eq- EarningsAug 06 AMC Payout- Avg Volume4.85M Price5.72
Recom3.30 SMA20-3.31% SMA50-0.59% SMA200-18.98% Volume3,439,459 Change0.09%
May-18-20Reiterated H.C. Wainwright Buy $29 → $33
Apr-27-20Downgrade SVB Leerink Mkt Perform → Underperform $5
Apr-09-20Downgrade BofA/Merrill Neutral → Underperform $6
Jan-08-20Reiterated H.C. Wainwright Buy $36 → $27
Nov-19-19Downgrade Evercore ISI Outperform → In-line $8
Sep-24-19Downgrade SVB Leerink Outperform → Mkt Perform $22 → $10
Aug-13-19Downgrade BofA/Merrill Buy → Neutral
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-29-19Downgrade Goldman Neutral → Sell
Apr-15-19Reiterated H.C. Wainwright Buy $39 → $37
Feb-13-19Initiated H.C. Wainwright Buy $40
Dec-04-18Upgrade Leerink Partners Mkt Perform → Outperform
Oct-31-18Downgrade JP Morgan Overweight → Neutral
Oct-19-18Resumed Piper Jaffray Neutral
Sep-25-18Initiated Leerink Partners Mkt Perform
Feb-22-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-22-18Upgrade Evercore ISI In-line → Outperform
Oct-23-17Initiated Barclays Overweight $105
Sep-15-17Initiated RBC Capital Mkts Sector Perform $81
Aug-17-17Initiated Evercore ISI In-line $73
Oct-20-20 04:05PM  
Oct-14-20 10:15PM  
Oct-13-20 06:47AM  
Sep-17-20 03:05AM  
Sep-10-20 08:05AM  
Sep-09-20 08:05AM  
Sep-08-20 04:19PM  
Sep-05-20 11:31AM  
Aug-27-20 09:58AM  
Aug-26-20 07:23PM  
Aug-18-20 10:36AM  
Aug-17-20 03:13PM  
Aug-07-20 11:44AM  
Aug-06-20 07:10PM  
Aug-05-20 08:05AM  
Jul-30-20 12:33PM  
Jul-23-20 08:00AM  
Jul-21-20 12:00PM  
Jul-15-20 09:17AM  
Jun-30-20 02:46PM  
Jun-23-20 08:37AM  
Jun-22-20 09:01AM  
Jun-17-20 08:00AM  
Jun-11-20 10:49AM  
Jun-10-20 04:05PM  
Jun-04-20 11:31AM  
May-28-20 08:00AM  
May-21-20 04:10PM  
May-19-20 06:53PM  
May-18-20 08:05PM  
May-16-20 11:31AM  
May-15-20 02:30PM  
May-14-20 10:18AM  
May-11-20 11:00AM  
May-06-20 11:17AM  
May-05-20 07:05PM  
May-03-20 09:25AM  
Apr-29-20 04:05PM  
Apr-28-20 12:34PM  
Apr-22-20 09:00AM  
Apr-21-20 04:05PM  
Apr-15-20 12:00PM  
Apr-14-20 05:08PM  
Apr-09-20 10:04AM  
Apr-03-20 05:50PM  
Mar-25-20 11:30AM  
Mar-20-20 09:36AM  
Mar-19-20 05:50PM  
Mar-11-20 05:50PM  
Mar-03-20 08:30AM  
Mar-02-20 04:00AM  
Feb-27-20 07:24AM  
Feb-26-20 09:02AM  
Feb-25-20 10:12AM  
Feb-24-20 06:15PM  
Feb-21-20 11:30AM  
Feb-19-20 10:13AM  
Feb-17-20 12:30PM  
Feb-13-20 08:30AM  
Feb-11-20 04:05PM  
Feb-06-20 03:34PM  
Feb-03-20 09:44AM  
Jan-31-20 08:16AM  
Jan-28-20 04:22PM  
Jan-22-20 03:56PM  
Jan-16-20 09:09AM  
Jan-15-20 04:11PM  
Jan-14-20 03:12PM  
Jan-07-20 07:26AM  
Jan-02-20 08:55AM  
Dec-29-19 09:40PM  
Dec-27-19 12:08PM  
Dec-18-19 10:31AM  
Dec-16-19 08:30AM  
Dec-10-19 08:35AM  
Dec-09-19 07:18AM  
Dec-08-19 03:16PM  
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rolfe LindseySee RemarksSep 21Sale6.851,74711,96750,997Sep 23 04:36 PM
IVERS-READ GILLIAN CSee RemarksSep 21Sale6.858385,740212,731Sep 23 04:31 PM
Gross Paul EdwardSee RemarksSep 03Sale5.304352,30626,704Sep 08 04:22 PM
IVERS-READ GILLIAN CSee RemarksSep 03Sale5.305532,931211,296Sep 08 04:19 PM
MUEHL DANIEL WSee RemarksSep 03Sale5.304352,30630,748Sep 08 04:16 PM
Rolfe LindseySee RemarksSep 03Sale5.306283,32848,948Sep 08 04:15 PM
MUEHL DANIEL WSee RemarksAug 26Sale5.072421,22730,477Aug 27 04:16 PM
Gross Paul EdwardSee RemarksAug 03Sale5.922,50614,83624,732Aug 05 05:01 PM
IVERS-READ GILLIAN CSee RemarksAug 03Sale5.921,6709,886210,934Aug 05 05:00 PM
MUEHL DANIEL WSee RemarksAug 03Sale5.922,50614,83628,471Aug 05 05:00 PM
Rolfe LindseySee RemarksAug 03Sale5.921,89911,24248,622Aug 05 05:00 PM
Rolfe LindseySee RemarksJun 22Sale6.741,72811,64746,772Jun 23 05:16 PM
IVERS-READ GILLIAN CSee RemarksJun 22Sale6.748295,587208,855Jun 23 05:15 PM
Gross Paul EdwardSee RemarksJun 03Sale7.034703,30423,009Jun 05 05:00 PM
IVERS-READ GILLIAN CSee RemarksJun 03Sale7.035984,204207,435Jun 05 05:00 PM
Rolfe LindseySee RemarksJun 03Sale7.036804,78044,731Jun 05 04:51 PM
MUEHL DANIEL WSee RemarksJun 03Sale7.034703,30426,748Jun 05 04:49 PM
MUEHL DANIEL WSee RemarksMay 27Sale6.912471,70726,494May 28 07:41 PM
Gross Paul EdwardSee RemarksMay 05Sale8.102,21317,92520,895May 07 04:45 PM
IVERS-READ GILLIAN CSee RemarksMay 05Sale8.101,47511,948207,095May 07 04:16 PM
MUEHL DANIEL WSee RemarksMay 05Sale8.102,21317,92524,334May 07 04:15 PM
Rolfe LindseySee RemarksMay 05Sale8.101,67713,58444,430May 07 04:15 PM
Rolfe LindseySee RemarksApr 06Option Exercise3.0823,03470,94559,091Apr 08 04:00 PM
IVERS-READ GILLIAN CSee RemarksMar 20Sale4.608293,813204,821Mar 23 04:44 PM
Rolfe LindseySee RemarksMar 20Sale4.601,7287,94936,057Mar 23 04:42 PM
IVERS-READ GILLIAN CSee RemarksMar 03Sale7.206054,356203,404Mar 05 04:17 PM
MUEHL DANIEL WSee RemarksMar 03Sale7.204753,42022,480Mar 05 04:17 PM
Gross Paul EdwardSee RemarksMar 03Sale7.204753,42019,041Mar 05 04:15 PM
Rolfe LindseySee RemarksMar 03Sale7.206874,94634,020Mar 05 04:16 PM
MUEHL DANIEL WSee RemarksFeb 27Sale6.902791,92522,227Mar 02 04:17 PM
MUEHL DANIEL WSee RemarksFeb 04Sale8.4110,47288,07015,117Feb 06 04:19 PM
IVERS-READ GILLIAN CSee RemarksFeb 04Sale8.417,20460,586203,067Feb 06 04:16 PM
Rolfe LindseySee RemarksFeb 04Sale8.417,50363,10033,722Feb 06 04:15 PM
Gross Paul EdwardSee RemarksFeb 04Sale8.4110,47088,05311,944Feb 06 04:15 PM
Rolfe LindseySee RemarksDec 20Sale11.301,72919,53826,228Dec 26 04:16 PM
IVERS-READ GILLIAN CSee RemarksDec 20Sale11.308309,379195,274Dec 26 04:15 PM
MUEHL DANIEL WSee RemarksDec 03Sale14.594666,7999,626Dec 05 04:06 PM
Rolfe LindseySee RemarksDec 03Sale14.606749,84124,185Dec 05 04:06 PM
IVERS-READ GILLIAN CSee RemarksDec 03Sale14.595928,640193,852Dec 05 04:05 PM
Gross Paul EdwardSee RemarksDec 03Sale14.594666,7996,192Dec 05 04:05 PM
MUEHL DANIEL WSee RemarksNov 26Sale10.202422,4689,369Nov 29 04:05 PM